Announcements Trials

Browse Landscape

Phase

Phase 2 7 Phase 3 2 Phase EARLY_PHASE1 1 Phase 1/2 1 Phase 1 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 1 Acrocephalosyndactylia 1

Interventions

Specimen Handling 51 pembrolizumab 46 Magnetic Resonance Spectroscopy 38 Biopsy 37 Cyclophosphamide 34 fludarabine 29 Cetuximab 20 Cisplatin 19 Carboplatin 19 Radiotherapy 16 Bevacizumab 16 atezolizumab 15 Radiation 15 venetoclax 14 Nivolumab 14 Fluorouracil 14 fludarabine phosphate 13 Leucovorin 13 Gemcitabine 13 Temozolomide 11 Pemetrexed 11 Oxaliplatin 11 Cytarabine 11 Paclitaxel 10 Irinotecan 10 Ipilimumab 10 130-nm albumin-bound paclitaxel 10 Prednisone 9 Immunoglobulin G 9 Fulvestrant 9

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × erdafitinib × 30 days × Clear all

NCT05567185 2026-06-05

TAR-210

Janssen Pharmaceutical K.K.

Phase 1 Active not recruiting

Acrocephalosyndactylia, Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡